anti-VEGF drugs

5-year CATT analysis finds anti-VEGF drugs a long-term AMD therapyAfter 5 years of follow-up in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), the visual acuity gains achieved during the first 2 years of anti-VEGF treatment were not maintained, the choroidal neovascular lesions continued to evolve with evidence of persistent activity in some eyes, and there was increased retinal thinning and geographic atrophy (GA).
Aflibercept rivals laser for diabetic retinopathyIntravitreal aflibercept worked better than panretinal photocoagulation (PRP) for proliferative diabetic retinopathy (PDR) in a new head-to-head trial, according to researchers. retinal treatment results take center stage in 2015Studies of the efficacy of anti-vascular endothelial growth factor (VEGF), gene therapies, and slow-release drug delivery systems took center stage among treatments for retinal disorders in 2015. In addition to studies already under way, others are about to begin.
Anti-VEGF drugs: Safe and effective for treating DMEData from large randomized trials indicate that diabetic macular edema can be treated safely and effectively with anti-vascular endothelial growth factor therapies.
Topical drug improves anti-VEGF effectiveness for retinal vein occlusionNew Ohr Pharmaceuticals formulation of topical squalamine was found to improve anti-VEGF effectiveness for the treatment of retinal vein occlusion.
Combo therapy improves VA in AMD patientsAnti-vascular endothelial growth factor (anto-VEGF) monotherapy is inadequate in patients with age-related macular degeneration (AMD). However, by adding an anti-platelet-derived growth factor (anti-PDGF) drug to the anti-VEGF regimen, treatment is enhanced by preventing the development of fibrosis thus improving visual outcomes, according to Usha Chakravarthy, MBBS, PhD.
Ranibizumab achieves higher BCVA gains for BRVO in COMRADE-BIn this article, Dr Simon Taylor discusses results of the key studies for both the ranibizumab anti-VEGF injection and the dexamethasone implant, including the higher BCVA gains achieved for BRVO with ranibizumab in COMRADE-B.
Lasting effects of anti-VEGF/photodynamic therapy for AMDThe authors present results from a retrospective chart review demonstrating effective management of exudative AMD using anti-VEGF/photodynamic combination therapy. Possible implications of these findings for clinical practice are also discussed.
Real-world experience: Positive DME treatment outcomes observed with FAc implant at UK centreDr Mushtaq discusses one centre’s initial post-marketing experience with the fluocinolone acetonide intravitreal implant 0.19 mg. The implant demonstrated favourable outcomes and good patient acceptance.
Questions remain if anti-VEGF therapy influences atrophy in neovascular AMD
Questions remain if anti-VEGF therapy influences atrophy in neovascular AMDAnalysis of the Harbor Study data could not definitively answer the question about whether anti-vascular endothelial growth factor (VEGF) therapies influence the development of atrophy in patients with neovascular age-related macular degeneration (AMD). However, investigators did find that the visual acuity (VA) continued to improve in patients treated with monthly and as-needed drug regimens and that certain risk factors can predict development of atrophy, according to Srinivas Sadda, MD.